Efficacy and safety of fluorouracil + epirubicin + cyclophosphamide (FEC) versus FEC + docetaxel in patients with high-risk node-negative breast cancer.
Phase of Trial: Phase III
Latest Information Update: 08 Dec 2012
At a glance
- Drugs Docetaxel (Primary) ; Cyclophosphamide; Epirubicin; Fluorouracil
- Indications Breast cancer
- Focus Therapeutic Use
- Acronyms NNBC3-Europe
- 08 Dec 2012 Results presented at the 35th Annual San Antonio Breast Cancer Symposium.
- 08 Dec 2012 The primary endpoint 'Disease-free-survival-rate' has not been met, as reported in SABCS abstract.
- 05 Nov 2010 New trial record.